HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral blood progenitor cell transplant: molecular follow-up of minimal residual disease.

Abstract
Plasma cell leukemia is a rare disease associated with very poor survival with standard treatment. We report a patient affected by plasma cell leukemia treated with aggressive chemotherapy and autologous CD34-selected PBPC who achieved a complete remission now lasting more than 2 years. Molecular studies confirmed the presence of minimal residual disease (MRD) despite the absence of disease activity. High-dose chemotherapy with stem cell rescue may be applied to selected patients considering the impact of the treatment on survival. The meaning of molecular MRD in this setting is unclear.
AuthorsS Sica, P Chiusolo, P Salutari, N Piccirillo, L Laurenti, E Ortu La Barbera, F G Serra, G Leone
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 22 Issue 8 Pg. 823-5 (Oct 1998) ISSN: 0268-3369 [Print] England
PMID9827984 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD34
Topics
  • Antigens, CD34
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Combined Modality Therapy
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia, Plasma Cell (pathology, therapy)
  • Middle Aged
  • Neoplasm, Residual
  • Remission Induction
  • Time Factors
  • Transplantation, Autologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: